¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Femhrt Low Dose Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • committed dose equivalent
    ¿¹Å¹¼±·®ÇØ´ç·®
  • committed effective dose
    ¿¹Å¹À¯È¿¼±·®
  • cumulative dose
    1. ´©Àû¿ë·® 2. ´©Àû¼±·®
  • curative dose
    1. Ä¡À¯¿ë·® 2. Ä¡À¯¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • depth dose curve
    ½ÉºÎ¼±·®°î¼±
  • dose
    1. ¿ë·®, Åõ¿©·® 2. ¼±·®, Á¶»ç·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
  • dose profile
    ¹æ»ç¼±·®Ãø¸éµµ
  • dose rate
    1. ¼±·®·ü 2. Åõ¿©·®
  • dose rate effect
    ¼±·®·üÈ¿°ú
  • dose rate meter
    ¼±·®·ü°è, ¼±·®·üÃøÁ¤±â
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
  • dose profile
    ¹æ»ç¼±·®Ãø¸éµµ
  • dose rate
    ¼±·®·ü
  • dose rate effect
    ¼±·®À²È¿°ú
  • dose rate meter
    ¼±·®À²°è, ¼±·®·üÃøÁ¤±â
  • dose rate variation
    ¼±·®·üº¯ÀÌ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • effective dose
    À¯È¿¿ë·®, À¯È¿¼±·®
  • erythema dose
    È«¹Ý¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • fatal dose
    Ä¡»ç¿ë·®, Ä¡»ç¼±·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
  • low vision aids
    Àú½Ã·Âº¸Á¶±â
  • low zone
    Àú¿ªÀÇ.
  • low-ionic--strength salt solution =LISS
    ÀúÀ̿°­µµ¿°¿ë¾×
  • low-ionic-strength salt solution TEST = LISS test
    ÀúÀ̿°­µµ¿°¿ë¾×
  • low-zone tolerance
    ¹Ì·®¸é¿ª°ü¿ë (Ç׿ø)
  • spontaneous low pressure headache
    ÀÚ¿¬¼º Àú¾Ð¼º µÎÅë(í»æÔàõî¸äâàõÔé÷Ô)
  • transduction, low frequency
    ÀúºóµµÇüÁúµµÀÔ
  • ultra low field MR scanner
    ÃÊÀúÀÚÀå ÀÚ±â°ø¸í½ºÄ³³Ê
  • very low density lipoprotein
    ±ØÀúºñÁßÁö´Ü¹é
  • very low density lipoprotein
    ÃÊÀú¹ÐµµÁö´Ü¹é(Áú)
  • very low density lipoprotein =VLDL
    ÃÊÀúºñÁßÁö(Áú)´Ü¹é(Áú).
  • very low-density lipoprotein =VLDL
    ÃÊÀú¹ÐµµÁö(Áú)´Ü¹é(Áú).
  • arch, oral
    ±¸°³±Ã, ÀÔ±Ã
  • bacteriology, oral
    ±¸°­¼¼±ÕÇÐ
  • character oral
    ±¸°­±â ¼º°Ý
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
ADD acceptable daily dose; adduction; adenosine deaminase; attentional deficit disorder; average daily d...
DED date of expected delivery; defined exposure dose; delayed erythema dose
HD Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ...
IAD inactivating dose; instructional advance directive; internal absorbed dose
MAD major affective disorder; mandibulo-acral dysplasia; maximum allowable dose; methylandrostenediol; m...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 7
OC Oral contraceptive
OCP Oral contraceptive pill
OCS Oral contraceptive steroids
OCA Oral contraceptives agents
OGTT Oral glucose tolerance
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • oral aphthae
    ±¸³» ¾ÆÇÁŸÁõ
    ±¸°­ Á¡¸·¿¡ ³ªÅ¸³ª´Â Àû»ö, ȸ»öÀÇ ÀÛÀº ¹ÝÁ¡À̳ª ±Ë¾ç.
  • oral arch
    ÀÔ±Ã, ±¸°³±Ã
  • oral cancer
    ±¸°­ ¾Ï
    Àüü ¾Ï ¹ß»ý ºóµµ¿¡¼­ ¾à 3¡­4%¸¦ Â÷ÁöÇÏ´Â ±¸°­ ¾ÏÀº Çô, »´, Ä¡ÁÖÁ¶Á÷, ¶Ç´Â ±¸ÀεÎÀÇ ¾î´À ºÎÀ§¿¡µµ ħ¹üÇÒ ¼ö ÀÖ´Ù. ÀÌ´Â ±¸°­ ³»ÀÇ ¹ß»ý À§Ä¡¿¡ µû¶ó ´Þ¶óÁö±â´Â ÇÏÁö¸¸ ´ë°³ ¿©ÀÚº¸´Ù´Â ³²ÀÚ¿¡°Ô¼­ ¾à 2~6¹è ¸¹ÀÌ ¹ß»ýÇÏ¸ç ¿ì¸® ³ª¶ó¿¡¼­´Â 1³â¿¡ ¾à õ ¸í ³»Áö ÀÌ Ãµ¸íÀÇ »õ·Î¿î ±¸°­ ¾Ï ȯÀÚ°¡ ¹ß»ýÇϱ⠶§¹®¿¡ ±¸°­ ¾ÏÀ¸·Î Åõº´ ÁßÀΠȯÀÚ¸¸µµ ¼ö ¸¸ ¸í¿¡ À̸¥´Ù. 1996³â¿¡ ½ÃÇàÇÑ ÈÄÇ⼺ ¿¬±¸¿¡ ÀÇÇϸé Àüü ±¸°­ ¾Ï ȯÀÚÀÇ Æò±Õ 5³â »ýÁ¸À²Àº ¾à 46%·Î ¹Ý ÀÌ»óÀÇ È¯ÀÚ°¡ 5³â À̳»¿¡ »ç¸ÁÇÏ´Â °ÍÀ¸·Î Á¶»çµÈ¹Ù ÀÖ´Ù. ±¸°­ ¾ÏÀÇ À¯º´·üÀº ¿¬·É Áõ°¡¿Í °ü·ÃÀÌ ÀÖ´Ù. 40¼¼ ÀÌÈÄ¿¡ ¹ß»ý·üÀÌ ±ØÀûÀ¸·Î Áõ°¡Çϱ⠽ÃÀÛÇÏ¿© 60¼¼ÀÇ ¿¬·É¿¡¼­ ÀÏÁ¤ÇÑ À¯Áö °î¼±À» Çü¼ºÇÑ´Ù. ¾î¶² ¿ä¼Ò°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Å« ¿µÇâÀ» ³¢Ä¡´Â°¡¿¡ ´ëÇÑ ¹®Çå ¿¬±¸¿¡¼­ ´ã¹è¿Í ¼úÀÌ ¸ðµç ±¸°­ ¾ÏÀÇ 75%¸¦ ¾ß±âÇØ ÀÌ Áúȯ¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. Èí¿¬°ú °úÀ½ÀÌ °¢°¢ ±¸°­ ¾ÏÀÇ À§Ç輺À» Áõ°¡½ÃŰ´Â ¹Ý¸é, ±×µéÀÇ »óÇÕÈ¿°ú´Â ±× ¸î ¹èÀÎ °ÍÀ¸·Î ³ªÅ¸³ª¼­ °ñÃÊ¿¡ ¾ËÄÝ Áßµ¶À̶ó¸é Á¤»óÀÎÀÇ ¾à 30¹è ÀÌ»ó ÀÌȯÀ²ÀÌ ³ô¾ÆÁø´Ù. ±¸°­ ¾ÏÀÇ ÈçÇÑ Àü±¸ Áõ»óÀ¸·Î ¾Ë·ÁÁø ¹é¹ÝÁõÀº ±¸°­ Á¡¸·¿¡ Èò ¹éŸ¦ º¸ÀÌ´Â º´º¯À¸·Î ÀÌ ÁúȯÀÌ ¾ÏÁ¾À¸·Î ÁøÇàµÉ È®·üÀº 0.1%~36%ÀÇ ¸Å¿ì ´Ù¾çÇÑ ÆíÂ÷·Î º¸°íµÇ°í ÀÖÀ¸³ª ÀϹÝÀûÀ¸·Î´Â 10Áõ·Ê Áß 1Áõ·Ê°¡ ÀÌÇàµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Àß ÀûÇÕµÇÁö ¾Ê´Â Ʋ´Ï³ª ¿À·¡ »ç¿ëÇÏ¿© ¸¶¸ðµÇ°í ³¯Ä«·Î¿öÁø ±Ý°ü µî¿¡ ÀÇÇÏ¿© Çù Á¡¸·À̳ª Çô, ¹«Ä¡¾Ç Ä¡Á¶Á¤ Á¡¸· µî¿¡ ¹ß»ýµÇ´Â ±Ë¾ç¼º º´º¯Àº Á¾±¹¿¡´Â ±¸°­ ¾ÏÀ¸·Î ÀüÀ̵DZ⠽¬¿î °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î ÁÖ±âÀûÀÎ Ä¡°ú °ËÁøÀÌ ÇÊ¿äÇÏ´Ù. ±¸°­ ¾ÏÀÇ À§Çè ¿ä¼Ò Áß¿¡´Â À¯ÀüÀû ¿ä¼Òµµ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ƯÁ¤ Áý´Ü Áß¿¡´Â ¾ÏÀ» °¡Áö°í ÀÖ´Â °¡Á·ÀÌ ÀÖÀ¸¸é ±¸°­ ¾ÏÀÇ ¹ß»ý À§Ç輺ÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Èí¿¬°ú À½ÁÖ°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Áß¿äÇÑ ¿äÀÎÀ̱⠶§¹®¿¡ Áß´ÜÇϰųª ÃÖ¼ÒÇÑ ÁÙÀÌ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù. °Ç°­ÇÑ ½Ä»ýȰÀº ±¸°­ ¾ÏÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù. ½Å¼±ÇÑ °úÀÏÀ̳ª ³ì»ö ä¼Ò´Â ±¸°­ ¾Ï ¹ß»ý·üÀ» °¨¼Ò½Ãų ¼ö ÀÖ°í, ÀÌ´Â ºñŸ¹Î A, C, E°¡ ÇÔÀ¯µÈ À½½ÄÀÌ ¿¹¹æ È¿°ú¸¦ °®´Â´Ù´Â »ç½ÇÀ» µÞ¹ÞħÇÑ´Ù. ±¸°­ Á¡¸·À» µ¥ÀÏ Á¤µµÀÇ ¶ß°Å¿î À½½ÄÀ̳ª ÀڱؼºÀÇ À½½ÄÀº ÇÇÇϵµ·Ï ÇÏ´Â °ÍÀÌ ÁÁ´Ù. HPVÀÇ ¹ßÇöÀ̳ª P53 À¯Àü ÀÎÀÚÀÇ º¯À§¿Í °°Àº ƯÁ¤ À¯ÀüÇÐÀû ¶Ç´Â Ãʱ⠼¼Æ÷ º¯È­°¡ ±¸°­ ¾Ï°ú °ü·ÃÀÌ ÀÖ´Ù´Â ¹ß°ßÀº ÃÖ±Ù ÁÖ¸ñ¹Þ°í ÀÖ´Â ¿¬±¸ÀÌ´Ù. °¡±î¿î ¹Ì·¡¿¡´Â ±¸°­ ¾ÏÀÇ À§Ç輺ÀÌ ³ôÀº ȯÀÚÀÇ ±¸°­ Á¡¸·À» ÁÖ±âÀûÀ¸·Î °Ë»çÇϰųª Ãʱ⠼¼Æ÷ º¯È­¸¦ º¸À̴ ȯÀÚ¸¦ ÀÎÁöÇÏ´Â °ÍÀÌ °¡´ÉÇÒ °ÍÀÌ´Ù. ±¸°­ ¾ÏÀÇ Á¶±â ¹ß°ß°ú Ä¡·á¸¦ À§ÇÑ À¯¿ëÇÑ ±â¼úÀÇ °³¹ßÀº ÀÌ ºÐ¾ß¿¡¼­ ±â´ëµÈ´Ù. ±¸°­ ¾ÏÀº ¹ß»ý Ãʱ⿡´Â º°´Ù¸¥ Áõ»óÀ» º¸ÀÌÁö ¾Ê°í ¼­¼­È÷ ÁøÇàµÇ±â ¶§¹®¿¡ Á¶±â ¹ß°ßÀÌ ¹«Ã´ ¾î·Æ´Ù. ±¸°­ ¾Ç¾È¸é ¿µ¿ªÀÇ ¾ÏÀÇ Á¶±â ¹ß°ßÀº ¿©·¯ °¡Áö ÀÓ»óÀûÀÎ ¹ß°ßÀÌ ±âÃʰ¡ µÇ´Âµ¥ Ãʱ⿡´Â ´ë°³ ºÓÀº È«¹ÝÁõÀ» º¸À̸ç Á¡¸·ÀÌ °ÅÄ¥¾îÁö°í ¾à°£ À¶±âµÇ³ª À̶§´Â ¿°Áõ¼º º´¼Ò¿Í ºñ½ÁÇÏ¿© °¨º°ÀÌ °ï¶õÇÏ´Ù. ÀÌÈÄ ÁøÇàµÇ¾î ÀԾȿ¡ Èò ¸·ÀÌ »ý±â°Å³ª ÀÔ¾ÈÀÌ Çæ¾î ±Ë¾çÀÌ »ý±â°í º¸¸§ ÀÌ»ó ³´Áö ¾Ê°í Áö¼ÓµÇ´Â °æ¿ìµµ ÀÖ´Ù. ÀԾȿ¡ ¸¸¼ºÀûÀ¸·Î ¹é»ö º´¼Ò°¡ ÀÖ´Â °æ¿ì, ¸ñ¿¡ ¸Û¿ïÀÌ »ý±â°í ¾ø¾îÁöÁö ¾Ê´Â °æ¿ì ±¸°­ ¾ÏÀÌ ÀǽɵǹǷΠÁ» ´õ ¼¼¹ÐÇÑ Áø´ÜÀ» ¹Þ¾Æº¸´Â °ÍÀÌ ±ÇÀåµÇ¸ç Á¶±â Áø´Ü ½Ã »ýÁ¸À²Àº ÇöÀúÇÏ°Ô ³ô¾ÆÁö°Ô µÈ´Ù. ±¸°­ ¾Ï Ä¡·á ¹æ¹ýÀº ´ëÇ¥ÀûÀ¸·Î ¿Ü°úÀû ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, Ç×¾Ï ¿ä¹ýÀ¸·Î ÀÌ·ç¾îÁö¸ç ´Üµ¶À¸·Î ¶Ç´Â º¹ÇÕÀûÀ¸·Î ½ÃÇàµÈ´Ù. ÃÖ±Ù¿¡ ¸é¿ª ¿ä¹ý, ±¤ ¿¡³ÊÁö ¿ä¹ý µîÀÌ °³¹ßµÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ÀÓ»óÀûÀ¸·Î Ȱ¹ßÈ÷ ÀÌ¿ëµÇ°í ÀÖÁö´Â ¸øÇÏ´Ù. ±¸°­ ¾Ç¾È¸é ºÎÀ§ÀÇ Á¾¾çÀÇ ÀýÁ¦ ½Ã¿¡´Â Åë»ó ¾Ç¾È¸é ºÎÀ§ÀÇ °á¼ÕÀ¸·Î ±â´É Àå¾Ö¿Í ¾È¸ð ÃßÇü µîÀÇ ½É¹ÌÀûÀÎ ¼Õ»ó°ú ÀÌ¿¡ µû¸¥ Á¤½Å ½É¸®Àû ¹®Á¦Á¡À» ¾ß±âÇÒ ¼ö ÀÖ´Ù. ±¸°­ ¾Ï ÀýÁ¦¼ú ÈÄ ¾Ç°ñ ¹× ¿¬Á¶Á÷ °á¼ÕÀÌ ÀÖ´Â °æ¿ì¿¡ ¾Ç°ñ Àç°ÇÀ» ´Ü¼øÈ÷ º¹¿øÀ̶ó´Â °³³äÀ» ¶°³ª ½É¹ÌÀûÀ̰í ÀúÀÛ ±â´ÉÀÇ È¸º¹À̶ó´Â Â÷¿ø¿¡¼­ Àç°ÇÇÏ¿© »çȸÀûÀ¸·Î º¹±ÍÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.
  • oral cavity
    ±¸°­
    ±¸°­Àº ÀÎü »ý¸í Çö»óÀ» À¯ÁöÇϱâ À§ÇÏ¿© À½½Ä¹°À» ¼·ÃëÇÏ´Â º»´ÉÀûÀÎ ÀúÀÛ ±â´ÉÀ» ÇÏ°í ¿¬ÇϽÃŰ¸ç ¹ßÀ½ ±â´ÉÀ» µµ¸ðÇÏ´Â ¼ÒÈ­±â °èÅëÀÇ Ã¹ °ü¹®ÀÌ´Ù. Á¦ÀÏ ¾Õ¿¡´Â ÀÔ¼ú°ú Ä¡¿­, »óºÎ¿¡´Â ±¸°³·Î ºñ°­°ú °æ°è¸¦ ÀÌ·ç¸ç Ãø¹æÀ¸·Î´Â ÇùºÎ·Î ¸·¾ÆÁø´Ù. ¶ÇÇÑ ÇϹ濡´Â Çô¿Í ¿¬Á¶Á÷ÀÌ ±¸°­Àú¸¦ ÀÌ·é´Ù. ÈĹæÀ¸·Î ¸ñÁ¥ ¹× Àεµ¿Í À̾îÁö¸ç ÈÄÃø¹æÀ¸·Î´Â Æíµµ¼±ÀÌ ÀÖ´Ù. ÇÑ ¸¶µð·Î ±¸°­Àº Àΰ£ÀÇ ¿©·¯ ±âÁö ¿å±¸¸¦ ÃæÁ·½ÃŰ´Â ±â°üÀÌ¸ç ¹°¸®Àû, ±â°èÀû, È­ÇÐÀû °¡±ØÀ» °¡Àå ½ÉÇÏ°Ô ¹Þ´Â ±â°üÀÌ´Ù.
  • oral character
    ±¸°­±â ¼º°Ý, ±¸¾Ö¼º ¼º°Ý
  • oral commissure
    ±¸°­ ±³·Ã
  • oral contraceptive
    °æ±¸¿ë ÇÇÀÓÁ¦
  • oral deformity
    ±¸°­ º¯Çü
  • oral diagnosis
    ±¸°­ Áø´Ü
  • oral diaphragm
    ±¸Àú Ⱦ°Ý¸·
  • oral dyskinesia
    ±¸°­ ¿îµ¿ ÀÌ»ó
  • oral effect of medication
    Åõ¾àÀÇ ±¸°­³» È¿°ú
  • oral eroticism
    ±¸¾Ö¼º »öÁ¤, ±¸°­±â »öÁ¤
  • oral floor
    ±¸°­Àú
  • oral fluid
    ±¸°­³» ºÐºñ¹°, ±¸°­¾×
    ±¸°­ ³»¿¡¼­ ºÐºñµÇ´Â ü¾×.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 7
therapeutic dose The quantity of any substance required to effect the cure of a disease or that will correct the manifestations of a deficiency of a particular factor in the diet, effective dose used with therapeutically applied compounds.
Synonym: therapeutic dose.
(05 Mar 2000)
effective dose The dose that produces the desired effect; when followed by a subscript (generally "ED50"), it denotes the dose having such an effect on a certain percentage (e.g., 50%) of the test animals; ED50 is the median effective dose, in radiation protection, the sum of the equivalent doses in all tissues and organs of the body weighted for tissue effects of radiation. The unit of effective dose is the sievert (Sv), epilation dose, the minimum amount of radiation sufficient to produce hair loss, usually in 10 to 14 days.
(05 Mar 2000)
tissue culture infectious dose The quantity of a cytopathogenic agent, such as a virus, that will produce a cytopathic effect in 50% of the cultures inoculated.
(05 Mar 2000)
tolerance dose The largest dose of a remedy that can be accepted without the production of injurious symptoms.
(05 Mar 2000)
equianalgesic dose The qualitative ratio between actual milligram potency of comparable analgesics required to achieve the equivalent therapeutic effect.
(05 Mar 2000)
equivalent dose In radiation protection, the absorbed dose averaged over a tissue or organ and weighted for the quality of the radiation of interest. The unit of equivalent dose is the sievert.
(05 Mar 2000)
erythema dose The minimum amount of X-rays or other form of radiation sufficient to produce erythema; historically, this dose was indicated by the Sabouraud meter as the B tint, the Holzknecht as 5(5H), the Hampson as 4, and the Kienbock as 10.
(05 Mar 2000)
exit dose The exposure dose of radiation leaving a body opposite the portal of entry.
(05 Mar 2000)
exposure dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
unit dose Occurring in or using a single dose, seen as a standard of measurement.
(18 Nov 1997)
usual dose This is the typical oral dose (all inhalational, suppository or injectables will be specified) given for a particular clinical situation. In most cases, the dose prescribed by your physician will be influenced by many factors including patient age, general health, health history, pregnancy, breast feeding, allergic history, weight and the specific disorder or disease that is being treated. Geriatric patients may be more sensitive to the usual dosage listed here. Pay close attention to the medication strength (in milligrams or grams) listed on the medication container. Caution: Dosage interval may vary with extended-release or Slow-Release preparations.
(27 Sep 1997)
fractional dose A definite fraction of a full dose; given repeatedly at short intervals so that the full dose is taken within a specified period, usually one day.
Synonym: fractional dose.
(05 Mar 2000)
L+ dose The limes tod dose of diphtheria toxin, i.e., the smallest amount of toxin that, when mixed with one unit of antitoxin and injected subcutaneously into a 250-g guinea pig, results in death of the animal within 96 hours (based on the average in a series); on theoretical grounds, one might expect that the difference between the L+ and L0 dose's would be identical to 1 MLD, but this is not so in actual practice; with various toxic filtrates, the difference may range from several to more than 100 MLD's, indicating that the toxin-antitoxin combination is not a firm chemical union that occurs in constant proportions.
(05 Mar 2000)
lethal dose <pharmacology> The amount, or dosage, of a toxin necessary to cause death.
(16 Mar 1998)
lethal dose 50 <pharmacology> The amount, or dosage, of a toxin necessary to kill 50% of the experimental subjects.
(16 Mar 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 7
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 7
ÅëÇÕ°Ë»ö ¿Ï·á